Galmed Pharmaceuticals receives Nasdaq delisting warning Jan 30, 2026 04:15PM
Galmed to present cancer research at HEP-DART 2025 conference Dec 8, 2025 08:32AM
Galmed receives South Korea patent for Aramchol-Rezdiffra combination Dec 4, 2025 08:32AM
Galmed CEO outlines drug development plans in shareholder letter Dec 1, 2025 08:30AM
Galmed reports three-drug combination shows enhanced tumor cell killing Nov 17, 2025 08:31AM


Aug 25, 2025 08:16AM Galmed Pharmaceuticals terminates licensing deal, plans minority stake
Aug 25, 2025 07:41AM Galmed Pharmaceuticals terminates licensing deal, plans minority stake
Aug 25, 2025 07:31AM Galmed plans to invest up to $10 million in digital assets
May 22, 2025 04:42PM Galmed Pharma (GLMD) Reports Q1 Loss of $0.62
Apr 15, 2025 08:32AM Galmed Pharma (GLMD) unveils novel PD blood markers for Aramchol
Sep 25, 2024 08:01AM Galmed Pharma (GLMD) reports Results from Aramchol Phase 3 Open Label part
Sep 19, 2024 07:06AM Galmed Pharma (GLMD) Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
Sep 17, 2024 04:38PM After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics